Compare WB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WB | MESO |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | WB | MESO |
|---|---|---|
| Price | $9.99 | $17.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 202.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 16.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.53 | $633.98 |
| Revenue Next Year | $2.38 | $29.51 |
| P/E Ratio | $5.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.10 | $9.61 |
| 52 Week High | $12.96 | $21.50 |
| Indicator | WB | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 46.75 |
| Support Level | $9.70 | $16.50 |
| Resistance Level | $10.37 | $18.38 |
| Average True Range (ATR) | 0.30 | 0.58 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 20.80 | 51.70 |
Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.